7 research outputs found
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β‑Peptide(1–42)
Tautomeric
state of histidine is one of the factors that influence
the structural and aggregation properties of amyloid β (Aβ)-peptide
in neutral state. It is worth it to uncover the monomeric properties
of Aβ(1–42) peptide in comparison with Aβ(1–40)
peptide. Our replica-exchange molecular dynamics simulations results
show that the sheet content of each tautomeric isomer in Aβ(1–42)
monomer is slightly higher than that in Aβ(1–40) monomer
except His6Â(δ)-His13Â(δ)-His14Â(δ) (δδδ)
isomer, implying higher aggregation tendency in AβÂ(1–42),
which is in agreement with previous experimental and theoretical studies.
Further analysis indicates that (εεε), (εδε),
(εδδ), and (δδε) isomers prefer
sheet conformation although they are in nondominating states. Particularly,
it is confirmed that antiparallel β-sheets of (εδδ)
were formed at K16-E22 (22.0–43.9%), N27-A30 except G29 (21.9–40.2%),
and M35-I41 except G37 (24.1–43.4%). Furthermore, (εδδ)
may be the easiest one to overcome structural transformation due to
nonobstructing interactions between K16 and/or L17 and histidine residues.
The current study will help to understand the tautomeric effect of
Aβ(1–42) peptide to overcome Alzheimer’s disease
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β‑Peptide(1–40)
Histidine
state (deprotonated, neutral, and protonated) is considered
an important factor influencing the structural properties and aggregation
mechanisms in amyloid β-peptides (Aβ), which are associated
with the pathogenesis of Alzheimer’s disease. Understanding
the structural properties and aggregation mechanisms is a great challenge
because two forms (the N<sup>ε</sup>–H or N<sup>δ</sup>–H tautomer) can exist in the free neutral state of histidine.
Here, replica-exchange molecular dynamics simulation was performed
to elucidate the changes in structure and the mechanism of aggregation
influenced by tautomeric behaviors of histidine in Aβ(1–40).
Our results show that sheet-dominating conformations can be found
in the His6Â(δ)–His13Â(δ)–His14Â(δ) (δδδ)
isomer with significant antiparallel sheet structures between R5–D7
and L34–G38, as well as between L17–F20 and L34–G38,
implying that a new aggregation mechanism may exist to promote the
generation of oligomers and/or aggregates. This work is helpful in
understanding the fundamental tautomeric behaviors of neutral histidine
in the process of aggregation
Zn<sup>2+</sup> Effect on Structure and Residual Hydrophobicity of Amyloid β‑Peptide Monomers
The aggregation of amyloid β-peptide
(Aβ peptide) has
been associated with the pathogenesis of Alzheimer’s disease
(AD). In the present study, we aimed to disclose how Zn<sup>2+</sup> affects the Aβ aggregation in detail. Thus, molecular dynamics
simulation was implemented to elucidate the changes of structure and
residual hydrophobicity upon Zn<sup>2+</sup> coordination. Our results
show that Zn<sup>2+</sup> can strongly influence the structural properties
of Aβ40 and Aβ42 by reducing helical formation and increasing
turn formation to expose the hydrophobic regions. Furthermore, hydrophobicity
of Zn<sup>2+</sup>-Aβ40 and Zn<sup>2+</sup>-Aβ42 was much
higher than that of each monomer, since Zn<sup>2+</sup> binding can
significantly influence the hydrophilic domains of Aβ. The further
analyses indicate that not only four residues (H6, E11, H13, and H14)
but also R5, D7, K16, K28, and terminal residues influence hydrophobicity
upon Zn<sup>2+</sup> coordination. Importantly, R5, K16, and K28 play
a crucial role to regulate solvation-free energies. This work is helpful
to understand the fundamental role of Zn<sup>2+</sup> in aggregation,
which could be useful for further development of new drugs to inhibit
Zn<sup>2+</sup>-Aβ aggregation
Ambient Degradation of Perylene Diimide-Based Organic Transistors: Hidden Role of Ozone and External Electric Field
A thorough interpretation
on the mechanisms that control the degradation
of the electrical performance of organic thin-film transistors (OTFTs)
during exposure to ambient environments is still developing. This
is particularly true for n-type OTFTs. By performing density functional
theory calculations, we have proposed a different degradation pathway
of perylene diimide in ambient air. Compared to the most common ambient
oxidant, O<sub>3</sub>, though seldom considered, can easily react
with >CC< in the π-conjugated charge-transfer
center
forming stable ozonides, which could be the underlying cause for relevant
device failures. It is noteworthy that external electric fields which
are ubiquitous while often overlooked in electronic devices can either
accelerate or hamper the degradation process depending on the field
direction. This finding underlines that in a rigid device configuration
where electrodes are largely fixed, the way the molecules align on
the substrate is pivotal to their ambient stability. Among the tested
substituents, cyanation at the periphery of the perylene core resists
O<sub>3</sub>/O<sub>2</sub> attack and favors electron transport by
lowering the internal reorganization energy. This work constitutes
the first step on understanding the interplay of interfacial oxidations
and molecular charge-transport properties toward modeling the bulk
electrical performance
Bioinspired Synthesis of Chiral 3,4-Dihydropyranones via S‑to‑O Acyl-Transfer Reactions
A bioinspired synthesis of chiral
3,4-dihydropyranones via S-to-O
acyl-transfer reactions is described. Asymmetric Michael addition–lactonization
reactions of β,γ-unsaturated α-keto esters with
thioesters are catalyzed by proline-derived urea, providing 3,4-dihydropyranones
and spiro-3,4-dihydrocoumarin-fused 3′,4′-dihydropyranones
in high yield (up to 94%) with excellent stereoselectivities (up to
>20:1 dr, 99% <i>ee</i>) under catalyst loadings as low
as 1 mol %
PLK1-Targeted Fluorescent Tumor Imaging with High Signal-to-Background Ratio
As significantly
expressed during cell division, polo-like kinase
1 (PLK1) plays crucial roles in numerous mitotic events and has attracted
interest as a potential therapeutic marker in oncological drug discovery.
We prepared two small molecular fluorescent probes, <b>1</b> and <b>2</b>, conjugated to <b>SBE13</b> (a type II
PLK1 inhibitor) to investigate the PLK1-targeted imaging of cancer
cells and tumors. Enzymatic docking studies, molecular dynamics simulations,
and <i>in vitro</i> and <i>in vivo</i> imaging
experiments all supported the selective targeting and visualization
of PLK1 expressing cells by probes <b>1</b> and <b>2</b>, and probe <b>2</b> was successfully demonstrated to image
PLK1-upregulated tumors with remarkable signal-to-background ratios.
These findings represent the first example of small-molecule based
fluorescent imaging of tumors using PLK1 as a target, which could
provide new avenues for tumor diagnosis and precision therapeutics
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach
A major
challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced
hypoxia, which can lead to cancer recurrence and progression through
activation of various angiogenic factors and significantly reduce
treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated
BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of
PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy
with PDT. AZ-BPS showed specific affinity to aggressive cancer cells
(MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX).
It displayed enhanced photocytotoxicity compared to a reference compound,
BPS, which is an analogous PDT agent that lacks an acetazolamide unit.
AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft
mouse tumor regrowth model relative to BPS, an effect attributed to
inhibition of tumor angiogenesis by both PDT-induced ROS generation
and CAIX knockdown. AZ-BPS was evaluated successfully in clinical
samples collected from breast cancer patients. We thus believe that
the combined approach described here represents an attractive therapeutic
approach to targeting CAIX-overexpressing tumors